We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

GeneBio's Phenyx Integrated with Proteome Software's Scaffold

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Geneva Bioinformatics (GeneBio) SA and Proteome Software have announced that GeneBio's Phenyx software platform for MS data analysis has been integrated into Proteome Software's Scaffold proteomics meta-analysis software.

Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio's renowned software platform for the identification and characterization of proteins and peptides from mass spectrometry data, designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment and offering a flexible user experience and an adaptable architecture to help instill confidence in results assessment.

Proteome Software's Scaffold meta-analysis software statistically validates peptides and proteins from tandem mass spectrometry results data. One of the many advantages of Scaffold is that it considers the results from multiple search engines amongst which are Phenyx, SEQUEST® or Mascot®, as well as optionally running X!Tandem on data files. This combination of results from several applications yields numerous cross-validated protein identifications, after which Scaffold displays the results in multiple biologically relevant formats.

"We strive to listen to our users to find out what tools they need us to support, and an ever-increasing number are asking that we incorporate results from Phenyx," said Mark Pitman of Proteome Software.

"This makes perfect sense, as it adds yet another high quality search engine to the Scaffold platform. We are always excited when we can deliver more value to our users, and we consider Phenyx to be of high value to our users and our overall platform," Pitman said.

"We are very pleased to have Phenyx join the list of results users can validate using Scaffold," said Nasri Nahas, CEO of GeneBio. "We are assured that our innovative approach to data analysis used in conjunction with the other leaders in the field will give Scaffold's users a level of results integrity hard to find elsewhere; everybody is a winner in this situation.